Information from Infant Bacterial Therapeutics Capital Markets Day 2017
September 8, 2017


Infant Bacterial Therapeutics has today, September 8, 2017, hosted a Capital Markets Day for investors, financial analysts and media in Stockholm.


The purpose of the Capital Markets Day was to present Infant Bacterial Therapeutics’ business, provide information about the disease necrotizing enterocolitis (IBP-9414 project) as well as the disease gastroschisis (IBP-1016 project).


Staffan Strömberg, the CEO of Infant Bacterial Therapeutics, also communicated that the company has received all data from the phase II safety and tolerability study (NCT02472769) for the lead drug candidate IBP-9414 and that the results will be communicated when analysis of the data is complete.


The presentation provided during the Capital Markets Day is available on the company’s website :


About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis (“NEC”), a fatal, rare disease that afflicts premature infants. The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.


IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.


IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser.


For additional information please contact

Staffan Strömberg, CEO

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

See the full press release in both English and Swedish

PR 20170908 CMD update ENG

PR 20170908 CMD update SWE


The presentation can be found via the below link

CMD Presentation